65 related articles for article (PubMed ID: 38535330)
1. Preoperative neoadjuvant targeted therapy remodels intra-tumoral heterogeneity of clear-cell renal cell carcinoma and ferroptosis inhibition induces resistance progression.
Chen WJ; Pan XW; Song X; Liu ZC; Xu D; Chen JX; Dong KQ; Di SC; Ye JQ; Gan SS; Wang LH; Zhou W; Cui XG
Cancer Lett; 2024 May; 593():216963. PubMed ID: 38768682
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-6 induces drug resistance in renal cell carcinoma.
Ishibashi K; Koguchi T; Matsuoka K; Onagi A; Tanji R; Takinami-Honda R; Hoshi S; Onoda M; Kurimura Y; Hata J; Sato Y; Kataoka M; Ogawsa S; Haga N; Kojima Y
Fukushima J Med Sci; 2018 Dec; 64(3):103-110. PubMed ID: 30369518
[TBL] [Abstract][Full Text] [Related]
3. Elucidation and Regulation of Tyrosine Kinase Inhibitor Resistance in Renal Cell Carcinoma Cells from the Perspective of Glutamine Metabolism.
Morozumi K; Kawasaki Y; Sato T; Maekawa M; Takasaki S; Shimada S; Sakai T; Yamashita S; Mano N; Ito A
Metabolites; 2024 Mar; 14(3):. PubMed ID: 38535330
[TBL] [Abstract][Full Text] [Related]
4. Metabolomic Analysis to Elucidate Mechanisms of Sunitinib Resistance in Renal Cell Carcinoma.
Sato T; Kawasaki Y; Maekawa M; Takasaki S; Morozumi K; Sato M; Shimada S; Kawamorita N; Yamashita S; Mitsuzuka K; Mano N; Ito A
Metabolites; 2020 Dec; 11(1):. PubMed ID: 33374949
[TBL] [Abstract][Full Text] [Related]
5. Adrenomedullin blockade suppresses sunitinib-resistant renal cell carcinoma growth by targeting the ERK/MAPK pathway.
Gao Y; Li J; Qiao N; Meng Q; Zhang M; Wang X; Jia J; Yang S; Qu C; Li W; Wang D
Oncotarget; 2016 Sep; 7(39):63374-63387. PubMed ID: 27556517
[TBL] [Abstract][Full Text] [Related]
6. PTEN Is Involved in Sunitinib and Sorafenib Resistance in Renal Cell Carcinoma.
Sekino Y; Hagura T; Han X; Babasaki T; Goto K; Inoue S; Hayashi T; Teishima J; Shigeta M; Taniyama D; Kuraoka K; Sentani K; Yasui W; Matsubara A
Anticancer Res; 2020 Apr; 40(4):1943-1951. PubMed ID: 32234883
[TBL] [Abstract][Full Text] [Related]
7. Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma.
Sharma R; Kadife E; Myers M; Kannourakis G; Prithviraj P; Ahmed N
J Exp Clin Cancer Res; 2021 Jun; 40(1):186. PubMed ID: 34099013
[TBL] [Abstract][Full Text] [Related]
8. Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma.
Bridgeman VL; Wan E; Foo S; Nathan MR; Welti JC; Frentzas S; Vermeulen PB; Preece N; Springer CJ; Powles T; Nathan PD; Larkin J; Gore M; Vasudev NS; Reynolds AR
Mol Cancer Ther; 2016 Jan; 15(1):172-83. PubMed ID: 26487278
[TBL] [Abstract][Full Text] [Related]
9. Cancer-cell-derived GABA promotes β-catenin-mediated tumour growth and immunosuppression.
Huang D; Wang Y; Thompson JW; Yin T; Alexander PB; Qin D; Mudgal P; Wu H; Liang Y; Tan L; Pan C; Yuan L; Wan Y; Li QJ; Wang XF
Nat Cell Biol; 2022 Feb; 24(2):230-241. PubMed ID: 35145222
[TBL] [Abstract][Full Text] [Related]
10. Update on the treatment of metastatic renal cell carcinoma.
Medina López RA; Rivero Belenchon I; Mazuecos-Quirós J; Congregado-Ruíz CB; Couñago F
World J Clin Oncol; 2022 Jan; 13(1):1-8. PubMed ID: 35116228
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy and Metastatic Renal Cell Carcinoma: A Review of New Treatment Approaches.
Kathuria-Prakash N; Drolen C; Hannigan CA; Drakaki A
Life (Basel); 2021 Dec; 12(1):. PubMed ID: 35054417
[TBL] [Abstract][Full Text] [Related]
12. A Combination of Glutaminase Inhibitor 968 and PD-L1 Blockade Boosts the Immune Response against Ovarian Cancer.
Wang JJ; Siu MK; Jiang YX; Leung TH; Chan DW; Wang HG; Ngan HY; Chan KK
Biomolecules; 2021 Nov; 11(12):. PubMed ID: 34944392
[TBL] [Abstract][Full Text] [Related]
13. Glutamine deficiency induces lipolysis in adipocytes.
Okuro K; Fukuhara A; Minemura T; Hayakawa T; Nishitani S; Okuno Y; Otsuki M; Shimomura I
Biochem Biophys Res Commun; 2021 Dec; 585():155-161. PubMed ID: 34801935
[TBL] [Abstract][Full Text] [Related]
14. Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067.
Regan MM; Mantia CM; Werner L; Tarhini AA; Larkin J; Stephen Hodi F; Wolchok J; Postow MA; Stwalley B; Moshyk A; Ritchings C; Re S; van Dijck W; McDermott DF; Atkins MB
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34799400
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
